Yankui Wang

Yankui Wang

Auto-generated profile, based on publicly available information

Yankui Wang

Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2018 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
YSYan Sun
Yan Sun
YWYankui Wang
Yankui Wang
WYWenhong Yu
Wenhong Yu
YZYan Zhuo
Yan Zhuo
QYQian Yuan
Qian Yuan
XWXiongfei Wu
Xiongfei Wu
BACKGROUND:Dialysis frequency and dose are controversial prognostic factors of hemodialysis morbidity and mortality. The aim of this study was to find out the effect of frequency and dosage of dialysis on mortality and survival in a group of Chinese ...

20 November 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
SDShixiang Dong
Shixiang Dong
XLXia Liu
Xia Liu
YWYankui Wang
Yankui Wang
The coronavirus disease 2019 (COVID-19) pandemic has been a major global focus since 2019. However, drug development and vaccination have been unable to stop the rise in the number of COVID-19 infections. As a result, almost everyone has been infected with COVID-19. As the COVID-19 pandemic nears its end, it is important to explore whether contracting COVID-19 has any irreversible effects on the female reproductive system. This article aims to review the effects of COVID-19 on the female ovary and reproductive system and examine whether these effects are permanent. In conclusion, we can state that COVID-19 has not caused any long-lasting effects on the reproductive health of most women, with the exception of a few cases where premature ovarian failure has been observed. These temporary effects, such as menstrual disturbances and temporary fertility loss, tend to diminish and eventually disappear over time.

5 September 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SDShixiang Dong
Shixiang Dong
YZYan Zhang
Yan Zhang
YWYankui Wang
Yankui Wang

6 December 2022 in Ginekologia Polska
Verified
Journal Article
Open access
PDF file
SDShixiang Dong
Shixiang Dong
FYFengsheng Yu
Fengsheng Yu
YLYutong Liu
Yutong Liu
XYXiao Yu
Xiao Yu
XSXin Sun
Xin Sun
YWYankui Wang
Yankui Wang
Objectives: To compare the clinical characteristics and prognosis of women with clear cell versus high-grade serous ovarian carcinoma. Material and methods: Retrospective analysis of the clinical data of 50 cases patients with ovarian clear cell carcinoma (OCCC) and 103 cases with high-grade serous ovarian carcinoma (HGSOC), who were initially treated and completed standardized therapy in Affiliated Hospital of Qingdao University from January 2013 to December 2017. Results: There were significant differences in age, gravidity (G > 1), chief complaint, with ovarian endometriosis, tumor diameter, unilateral or bilateral, cystic and solid tumor, CA125, HE4, CA199, lactate dehydrogenase (LDH), and FIGO stage between the two groups. The differences in the prognosis between OCCC patients and HGSOC patients with early stage (FIGO I–II) were not statistically significant. The 5-year overall survival and progression-free survival of OCCC patients were significantly worse than those of HGSOC patients with advanced stage (FIGO III–IV) (p < 0.05). FIGO stage and non-R0 resection were independent risk factors affecting the prognosis of patients with ovarian clear cell carcinoma, screening by Cox regression analysis. FIGO stage, the lowest value of CA125, and non-R0 resection were independent risk factors affecting the prognosis of patients with high-grade serous ovarian cancer. Conclusions: The clinical characteristics and prognosis of OCCC are different from those of HGSOC. Ovarian clear cell carcinoma (OCCC) patients have a significantly worse prognosis than those with HGSOC in the advanced stage (FIGO Ⅲ–Ⅳ). Satisfactory tumor resection is an essential factor related to the prognosis of patients with OCCC and HGSOC. Objectives: To compare the clinical characteristics and prognosis of women with clear cell versus high-grade serous ovarian carcinoma. Material and methods: Retrospective analysis of the clinical data of 50 cases patients with ovarian clear cell carcinoma (OCCC) and 103 cases with high-grade serous ovarian carcinoma (HGSOC), who were initially treated and completed standardized therapy in Affiliated Hospital of Qingdao University from January 2013 to December 2017. Results: There were significant differences in age, gravidity (G > 1), chief complaint, with ovarian endometriosis, tumor diameter, unilateral or bilateral, cystic and solid tumor, CA125, HE4, CA199, lactate dehydrogenase (LDH), and FIGO stage between the two groups. The differences in the prognosis between OCCC patients and HGSOC patients with early stage (FIGO I–II) were not statistically significant. The 5-year overall survival and progression-free survival of OCCC patients were significantly worse than those of HGSOC patients with advanced stage (FIGO III–IV) (p < 0.05). FIGO stage and non-R0 resection were independent risk factors affecting the prognosis of patients with ovarian clear cell carcinoma, screening by Cox regression analysis. FIGO stage, the lowest value of CA125, and non-R0 resection were independent risk factors affecting the prognosis of patients with high-grade serous ovarian cancer. Conclusions: The clinical characteristics and prognosis of OCCC are different from those of HGSOC. Ovarian clear cell carcinoma (OCCC) patients have a significantly worse prognosis than those with HGSOC in the advanced stage (FIGO Ⅲ–Ⅳ). Satisfactory tumor resection is an essential factor related to the prognosis of patients with OCCC and HGSOC.

19 April 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
XYXiao Yu
Xiao Yu
SDShixiang Dong
Shixiang Dong
WWWenjie Wang
Wenjie Wang
XSXin Sun
Xin Sun
YWYankui Wang
Yankui Wang
FYFengsheng Yu
Fengsheng Yu
Background: The treatment outcomes and prognosis for recurrent cervical cancer are generally poor, with a 5-year survival rate of only 10%–20%.Case presentation: In this case, the patient is a young woman who experienced a recurrence 5 years after the initial treatment of cervical cancer. Her primary symptoms were hemoptysis and dysphagia, indicative of hilar and mediastinal lymph node metastases, with further involvement of the bronchus and esophagus. Additionally, the patient also presented with tumor-associated dermatomyositis. Following combined treatment with albumin-bound paclitaxel, carboplatin, bevacizumab, and cadonilimab, the patient’s tumor was effectively controlled.

10 October 2019 in Clinical and Experimental Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
LYL. Yuanmei
L. Yuanmei
ZQZ. Qian
Z. Qian
XFX. Fengsen
X. Fengsen
WYW. Yankui
W. Yankui
IMR Press is a leading publisher of open access peer-reviewed biomedical and life sciences journals. We aim to facilitate the dissemination of high-quality research in the area of biomedical science. With a long tradition and wide readership, IMR Press is dedicated to making positive contributions to academics, corporate libraries as well as to readers and authors. All the editors in IMR Press will provide the best service for researchers, allowing them to have a easy and smooth publication experience and helping maximize the impact and visibility of their research.